Literature DB >> 17213427

Reproducibility of the whole-brain N-acetylaspartate level across institutions, MR scanners, and field strengths.

B Benedetti1, D J Rigotti, S Liu, M Filippi, R I Grossman, O Gonen.   

Abstract

BACKGROUND AND
PURPOSE: Radiologic markers in multicenter trials are often confounded by different instrumentation used. Our goal was to estimate the variance of the global concentration of the neuronal cell marker N-acetylaspartate (NAA) among research centers using MR imaging scanners of different models, from different manufacturers, and of different magnetic field strength.
MATERIALS AND METHODS: Absolute millimolar amounts of whole-brain NAA (WBNAA) were quantified with nonlocalizing proton MR spectroscopy in the brains of 101 healthy subjects (53 women, 48 men) aged 16-59 years (mean, 34.2 years). Twenty-three were scanned at 1 institute in a 1.5T Siemens Vision; 31 from another institute were studied with a 1.5T Siemens SP63; 36 were scanned at a third institute (24 with a 1.5T Vision, 12 with a 3T Siemens Trio); and 11 were obtained at a fourth institute using a 4T GE Signa 5.x. The NAA amounts were quantified with phantom-replacement and divided by the brain volume, segmented from MR imaging, to yield the concentration, a metric independent of brain size suitable for cross-sectional comparison.
RESULTS: The average WBNAA concentration among institutions was 12.2 +/- 1.2 mmol/L. The subjects' WBNAA distributions did not differ significantly (p > .237) among the 4 centers, regardless of scanner manufacturer, model, or field strength and irrespective of whether adjustments were made for age or sex.
CONCLUSION: Absolute quantification against a standard makes the WBNAA concentration insensitive to the MR hardware used to acquire it. This important attribute renders it a robust surrogate marker for multicenter neurologic trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17213427      PMCID: PMC8134079     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  31 in total

1.  Reproducibility of magnetization transfer ratio histogram-derived measures of the brain in healthy volunteers.

Authors:  M P Sormani; G Iannucci; M A Rocca; G Mastronardo; M Cercignani; L Minicucci; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2000-01       Impact factor: 3.825

2.  Interscanner variation in brain MRI lesion load measurements in MS: implications for clinical trials.

Authors:  M Filippi; J H van Waesberghe; M A Horsfield; S Bressi; C Gasperini; T A Yousry; M L Gawne-Cain; S P Morrissey; M A Rocca; F Barkhof; G J Lycklama à Nijeholt; S Bastianello; D H Miller
Journal:  Neurology       Date:  1997-08       Impact factor: 9.910

3.  Quantitative proton MR spectroscopic imaging of the human brain.

Authors:  B J Soher; P C van Zijl; J H Duyn; P B Barker
Journal:  Magn Reson Med       Date:  1996-03       Impact factor: 4.668

4.  Total brain N-acetylaspartate: a new measure of disease load in MS.

Authors:  O Gonen; I Catalaa; J S Babb; Y Ge; L J Mannon; D L Kolson; R I Grossman
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

Review 5.  Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis.

Authors:  M Filippi; M A Horsfield; P S Tofts; F Barkhof; A J Thompson; D H Miller
Journal:  Brain       Date:  1995-12       Impact factor: 13.501

Review 6.  In-vivo tissue characterization of multiple sclerosis and other white matter diseases using magnetic resonance based techniques.

Authors:  M Filippi
Journal:  J Neurol       Date:  2001-12       Impact factor: 4.849

7.  Reproducibility of 1H-MRS in vivo.

Authors:  W M Brooks; S D Friedman; C A Stidley
Journal:  Magn Reson Med       Date:  1999-01       Impact factor: 4.668

8.  Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis.

Authors:  Matilde Inglese; Yulin Ge; Massimo Filippi; Andrea Falini; Robert I Grossman; Oded Gonen
Journal:  Neuroimage       Date:  2004-04       Impact factor: 6.556

9.  The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study.

Authors:  P D Molyneux; P A Brex; C Fogg; S Lewis; C Middleditch; F Barkhof; M P Sormani; M Filippi; D H Miller
Journal:  Mult Scler       Date:  2000-08       Impact factor: 6.312

Review 10.  Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: consensus report of the White Matter Study Group.

Authors:  M Filippi; V Dousset; H F McFarland; D H Miller; R I Grossman
Journal:  J Magn Reson Imaging       Date:  2002-05       Impact factor: 4.813

View more
  16 in total

1.  Longitudinal whole-brain N-acetylaspartate concentration in healthy adults.

Authors:  D J Rigotti; I I Kirov; B Djavadi; N Perry; J S Babb; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2011-04-21       Impact factor: 3.825

Review 2.  A systematic review of the utility of 1.5 versus 3 Tesla magnetic resonance brain imaging in clinical practice and research.

Authors:  Joanna M Wardlaw; Will Brindle; Ana M Casado; Kirsten Shuler; Moira Henderson; Brenda Thomas; Jennifer Macfarlane; Susana Muñoz Maniega; Katherine Lymer; Zoe Morris; Cyril Pernet; William Nailon; Trevor Ahearn; Abdul Nashirudeen Mumuni; Carlos Mugruza; John McLean; Goultchira Chakirova; Yuehui Terry Tao; Johanna Simpson; Andrew C Stanfield; Harriet Johnston; Jehill Parikh; Natalie A Royle; Janet De Wilde; Mark E Bastin; Nick Weir; Andrew Farrall; Maria C Valdes Hernandez
Journal:  Eur Radiol       Date:  2012-06-09       Impact factor: 5.315

3.  Newfound effect of N-acetylaspartate in preventing and reversing aggregation of amyloid-beta in vitro.

Authors:  Jean-Pierre Dollé; Jeffrey M Rodgers; Kevin D Browne; Thomas Troxler; Feng Gai; Douglas H Smith
Journal:  Neurobiol Dis       Date:  2018-05-31       Impact factor: 5.996

4.  Global N-acetylaspartate in normal subjects, mild cognitive impairment and Alzheimer's disease patients.

Authors:  Lidia Glodzik; Marc Sollberger; Achim Gass; Amit Gokhale; Henry Rusinek; James S Babb; Jochen G Hirsch; Michael Amann; Andreas U Monsch; Oded Gonen
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

5.  Whole brain N-acetylaspartate concentration is conserved throughout normal aging.

Authors:  William E Wu; Achim Gass; Lidia Glodzik; James S Babb; Jochen Hirsch; Marc Sollberger; Lutz Achtnichts; Michael Amann; Andreas U Monsch; Oded Gonen
Journal:  Neurobiol Aging       Date:  2012-01-14       Impact factor: 4.673

6.  Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment.

Authors:  D J Rigotti; A Gass; L Achtnichts; M Inglese; J S Babb; Y Naegelin; J Hirsch; M Amann; L Kappos; O Gonen
Journal:  Mult Scler       Date:  2011-09-15       Impact factor: 6.312

7.  Global N-acetylaspartate declines even in benign multiple sclerosis.

Authors:  D J Rigotti; O Gonen; R I Grossman; J S Babb; A Falini; B Benedetti; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-10-21       Impact factor: 3.825

Review 8.  Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders.

Authors:  D J Rigotti; M Inglese; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-05       Impact factor: 3.825

9.  Global average gray and white matter N-acetylaspartate concentration in the human brain.

Authors:  Matilde Inglese; Henry Rusinek; Ilena C George; James S Babb; Robert I Grossman; Oded Gonen
Journal:  Neuroimage       Date:  2008-03-04       Impact factor: 6.556

10.  Selegiline and oxidative stress in HIV-associated cognitive impairment.

Authors:  G Schifitto; C T Yiannoutsos; T Ernst; B A Navia; A Nath; N Sacktor; C Anderson; C M Marra; D B Clifford
Journal:  Neurology       Date:  2009-11-04       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.